An In Vivo 24-Hour Recovery Study of Leukoreduced RBCs After Automated Separation of Whole Blood by the Reveos System and Storage for 42 Days

This is an in vivo 24-hour recovery study of leukoreduced red blood cells (RBCs) after automated separation of whole blood by the Reveos Automated Blood Processing System and storage for 42 days.

Study Overview

• Status: Completed
• Conditions: Device Validation of In-vivo Performance
• Intervention / Treatment: Device: Reveos® Automated Blood Processing System

Detailed Description

The Reveos® Automated Blood Processing System (Reveos system) is an automated whole blood processing system, not cleared for use in the United States. The Reveos System has been available outside the United States since 2012 and is seeking United States Food and Drug Administration (FDA) 510(k) clearance as an automated whole blood processor. The Reveos System is an integrated manufacturing system that processes whole blood (WB) units into blood components and is designed to minimize manual blood processing variables resulting from processing time, product and procedural variability. The Reveos System can simultaneously process up to 4 whole blood units into 4 RBC units, 4 leukoreduced plasma units, and 4 interim platelet units (IPU). The CPD/AS-5 RBC product is leukoreduced and may be stored up to 42 days.

Terumo BCT is seeking 510(k) clearance from FDA/CBER for the Reveos® Automated Blood Processing System (Reveos System). The proposed study will provide validation on the in vivo performance of LR-RBC units derived from WB processed with the Reveos System. The results will provide data as to whether the Reveos System produced LR-RBC can maintain required levels of 24-hour in vivo recovery that meet FDA criteria for RBC.

• Study Type: Observational
• Enrollment (Actual): 33

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cincinnati, Ohio, United States, 45267
      • Hoxworth Blood Center, University of Cincinnati
  • Washington
    • Seattle, Washington, United States, 98102
      • Bloodworks Northwest Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Community and research blood donors in the greater Seattle and Cincinnati areas.

Description

Inclusion Criteria:

1. Healthy volunteers, of either gender
2. Age 18 years or older.
3. Normal health status as per AABB criteria for healthy donor.
4. Able to commit to the study schedule.
5. Meets the inclusion criteria defined by the Blood Center for whole blood donor. These criteria are based on FDA Regulations and AABB standards. Note: Participants who are deferred from volunteer community donations because of travel restrictions, piercings, tattoos or other reasons by PI approval may participate in the study, as products are re-transfused to the autologous donor.
6. Participants of childbearing potential (either male or female) must agree to use medically acceptable method of contraception throughout of the study.
7. Females of childbearing potential must be willing to take a pregnancy test prior to WB donation and infusion of radiolabeled RBCs.
8. Signed and dated informed consent form.

Exclusion Criteria:

1. Pregnant or nursing females.
2. Serum ferritin <12 ng/mL
3. Has previously completed this study with evaluable data points.
4. Participation currently, or within the past 30 days, in another investigational trial that would potentially interfere with the analysis of this investigation (eg, pharmaceutical).

5. As determined by the Investigator

   1. Has been diagnosed with a blood disorder(s) affecting RBC characteristics (eg, G- 6PD).
   2. Reported history of RBC autoantibodies/autoimmune hemolytic anemia, RBC alloantibodies.
   3. Clinically significant acute or chronic disease
   4. Reported history of known hypersensitivity to technetium or chromium.
   5. Treatment with any medication as specified in site deferral list (based on AABB medication deferral list for blood donors).
6. Other unspecified reasons that, in the opinion of the investigator make the subject unsuitable for enrollment.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Healthy adult participants; Performance criteria will be evaluated in healthy adult participants, who receive radiolabeled, autologous infusions of LR-RBC components after being stored for 42 days at 1-6°C.	Device: Reveos® Automated Blood Processing System; This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean 24-hour, post-transfusion, in vivo RBC recovery percentage after 42-day storage	The primary outcome of this study is to measure mean 24-hour, post-transfusion, in vivo RBC recovery percentage after LR-RBCs derived from WB and processed with the Reveos System have been stored for 42-days at 1-6°C. The 3 parts of FDA's RBC recovery criteria that must be met are presented below. The derivation of the sample size was based on the level of precision attained with 24 subjects relative to the 1st part of the criteria.; The one-sided 95% lower confidence limit for the population proportion of success is greater than 70% where success of a unit is defined as the RBC in vivo 24-hour percentage recovery≥ 75%*,; The sample mean of percent recovery ≥ 75%, and; The sample standard deviation of in vivo 24-hour RBC recovery ≤ 9%. *Allows for low recoveries (<75%) in 2/20 or 3/24 volunteers.	43 days

Collaborators and Investigators

• Sponsor: Terumo BCT
• Investigators: Principal Investigator: Jose A Cancelas, MD, PhD, Hoxworth Blood Center, University of Cincinnati; Principal Investigator: Moritz Stolla, MD, PhD, Bloodworks Northwest Research Institute; Study Chair: James Kelley, MD, PhD, Terumo BCT

Study record dates

Study Major Dates

• Study Start (Actual): November 11, 2021
• Primary Completion (Actual): April 30, 2022
• Study Completion (Actual): April 30, 2022

Study Registration Dates

• First Submitted: January 3, 2022
• First Submitted That Met QC Criteria: February 10, 2022
• First Posted (Actual): February 14, 2022

Study Record Updates

• Last Update Posted (Actual): July 7, 2022
• Last Update Submitted That Met QC Criteria: July 5, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Reveos; Reveos Device; Reveos System; Red Blood Cell Storage; Whole Blood Processing; In-vivo 24-hour red blood cell recovery; Reveos System Manager; Reveos SELECT Set US; Reveos In Vivo US
• Other Study ID Numbers: CTS-5085

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes